Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552916 | 0.82 | EPHX2 (0.39) | BCHEMAOBEGFRERBB2KMT2A | |
| SCHEMBL3563880 | 0.69 | MAPK1 (0.42) | KMT2AMEN1CYP3A4MAPTNPSR1 | |
| SCHEMBL2769294 | 0.64 | EGFR (0.46) | EGFRKMT2AMEN1ACHE | |
| SCHEMBL2767484 | 0.63 | ALDH1A1 (0.46) | MAOBMAOAMAPTHTR2A | |
| SCHEMBL21667956 | 0.62 | FFAR1 (0.58) | BCHEKMT2AMEN1CYP3A4MAPT | |
| SCHEMBL18169335 | 0.60 | L3MBTL1 (0.48) | PKMMAPTTDP1 | |
| SCHEMBL7163366 | 0.60 | BCHE (0.48) | BCHEMAOBMAOAEGFRERBB2 | |
| SCHEMBL4228617 | 0.60 | FFAR1 (0.66) | BCHEKMT2ACYP3A4MAPTTDP1 | |
| SCHEMBL30002764 | 0.60 | FFAR1 (0.66) | BCHEKMT2ACYP3A4MAPTTDP1 | |
| SCHEMBL7290118 | 0.59 | BCHE (0.60) | BCHEMAOBMAOAEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696238-B2 | Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics | GRUENENTHAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | KCNQ1, KCNQ2, KCNQ3 | BCHE 3774/4885MAOB 1172/4885MAOA 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.